...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Degenerative Neurological and Neuromuscular Disease >Intravenous immunoglobulin for the treatment of Alzheimer's disease: current evidence and considerations
【24h】

Intravenous immunoglobulin for the treatment of Alzheimer's disease: current evidence and considerations

机译：静脉免疫球蛋白治疗阿尔茨海默氏病：最新证据和考虑因素

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract: Alzheimer's disease (AD) is a devastating neurodegenerative form of dementia with increasing incidence rates in most countries. AD is characterized by amyloid plaques and neurofibrillary tangles in the brains of AD individuals accompanied by global neuronal loss. The peptide amyloid-β (Aβ) aggregates to amyloid plaques in AD brains. As a result, many therapeutic approaches target Aβ. Human plasma and the plasma product intravenous immunoglobulin (IVIG) contain naturally-occurring anti-Aβ antibodies (Nabs-Aβ) that appear to reduce risks of developing AD. IVIG sequesters Aβ and thus interferes with AD progression. This study reviews the role of different Aβ species, Nabs-Aβ, preclinical data, and clinical studies of IVIG as potential AD treatments. The focus of this study is the outcomes of a recent Gammaglobulin Alzheimer's Partnership Phase III trial that did not reach primary endpoints, as well as efforts to compare IVIG with current anti-Aβ monoclonals such as bapineuzumab, solanezumab, and BIIB037. Moreover, this study critically examines current market and ethical consequences of potential off-label uses of IVIG, limits in IVIG supply, and subsequent challenges.
机译：摘要：阿尔茨海默氏病（AD）是一种毁灭性的痴呆神经退行性形式，在大多数国家中发病率均在上升。 AD的特征在于AD个体的大脑中淀粉样蛋白斑块和神经原纤维缠结，并伴有整体神经元丢失。肽淀粉样蛋白-β（Aβ）在AD脑中聚集为淀粉样斑块。结果，许多治疗方法靶向Aβ。人血浆和血浆产品静脉内免疫球蛋白（IVIG）包含天然存在的抗Aβ抗体（Nabs-Aβ），似乎可以降低罹患AD的风险。 IVIG螯合Aβ，从而干扰AD进展。这项研究综述了不同的Aβ物种，Nabs-Aβ，临床前数据以及IVIG作为潜在AD治疗的临床研究的作用。这项研究的重点是最近的一项Gammaglobulin Alzheimer的Partnership III期试验的结果，该试验尚未达到主要终点，以及将IVIG与目前的抗Aβ单克隆抗体（如bapineuzumab，solanezumab和BIIB037）进行比较的努力。此外，本研究严格审查了IVIG潜在不合规定使用的当前市场和伦理后果，IVIG供应的限制以及随后的挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号